ArticlePituitary2026
Prolactinoma assessment and management: an international multidisciplinary cross-sectional survey of current practice.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProlactinomas are the commonest pituitary adenoma encountered in clinical practice, yet many aspects of their assessment and management remain variable. The 2023 Pituitary Society Consensus Statement on the diagnosis and management of prolactin-secreting pituitary adenomas provided important contemporary guidance, but the extent to which current practice aligns with these recommendations remains unclear. We aimed to define international multidisciplinary perspectives on resource availability and clinical decision-making in prolactinoma care.
methodsWe conducted an international cross-sectional survey of endocrinologists and neurosurgeons involved in prolactinoma management. Questions examined access to clinical resources, awareness of emerging issues in prolactinoma care, and areas of concordance or discordance between reported practice and published guidance.
resultsA total of 249 clinicians completed the survey, including 210 endocrinologists and 39 neurosurgeons, from America, Europe, Oceania and Asia. Important resource limitations included inconsistent reporting of Knosp grade and limited availability of transcription factor immunohistochemistry. Only 20% of respondents routinely referred newly diagnosed prolactinoma cases for multidisciplinary team discussion. Most endocrinologists counselled patients regarding dopamine agonist-related risks. Amongst neurosurgeons, reported indications for surgery and views on dopamine agonist-induced tumour fibrosis varied considerably. Although current guidelines support surgery as an equal first-line option in selected microadenomas, cabergoline remained the preferred initial treatment in these scenarios.
conclusionInternational prolactinoma practice is heterogeneous and often discordant with contemporary guidance. Most notably, cabergoline therapy remains the preferred treatment strategy in microprolactinomas, and multidisciplinary discussion of prolactinoma cases is infrequent. This survey dataset serves as a roadmap for future research and clinical service improvement in prolactinoma care globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.